Edition:
United Kingdom

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

49.14USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$49.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
336,937
52-wk High
$65.51
52-wk Low
$39.08

Summary

Name Age Since Current Position

Stanley Crooke

72 1991 Chairman of the Board, President, Chief Executive Officer

Elizabeth Hougen

56 2013 Chief Financial Officer, Senior Vice President - Finance

Brett Monia

56 2018 Chief Operating Officer and Senior Vice President, Drug Discovery and Corporate Development

Patrick O'Neil

44 2016 Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary

C. Frank Bennett

61 2006 Senior Vice President - Antisense Research

Richard Geary

60 2008 Senior Vice President - Development

B. Lynne Parshall

64 2018 Director, Senior Strategic Advisor

Damien McDevitt

2018 Chief Business Officer

Spencer Berthelsen

65 2002 Independent Director

Breaux Castleman

77 2013 Independent Director

Joseph Klein

56 2005 Independent Director

Joseph Loscalzo

66 2016 Independent Director

Frederick Muto

64 2001 Independent Director

Joseph Wender

73 1994 Independent Director

D. Wade Walke

2018 Vice President, Investor Relations

Biographies

Name Description

Stanley Crooke

Dr. Stanley T. Crooke, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Ionis Pharmaceuticals Inc. Prior to founding Ionis, from 1980 until January 1989, Dr. Crooke worked for SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. Dr. Crooke serves on the board of directors of Akcea Therapeutics, Inc., a biopharmaceutical company. The Board believes Dr. Crooke is uniquely suited to serve on the Board primarily because, as the Chief Executive Officer and founder of Ionis, he has dedicated nearly 31 years to discovering and developing antisense, our technology platform. He is the named inventor on some of the key patents in the field of RNA-targeted therapeutics, and has nearly 40 years of drug discovery and development experience.

Elizabeth Hougen

Ms. Elizabeth L. Hougen is Chief Financial Officer, Senior Vice President - Finance of Ionis Pharmaceuticals Inc. From January 2007 to December 2012, Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as our Vice President, Finance. Prior to joining Ionis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.

Brett Monia

Dr. Brett P. Monia, Ph.D., is Chief Operating Officer and Senior Vice President, Drug Discovery and Corporate Development of Ionis Pharmaceuticals Inc. From February 2009 to January 2012, Dr. Monia served as our Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009, he served as our Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within our Molecular Pharmacology department.

Patrick O'Neil

Mr. Patrick R. O'Neil, Esq., is Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary of Ionis Pharmaceuticals Inc. Mr. O'Neil also serves as our Chief Compliance Officer and Corporate Secretary. From September 2010 to January 2013, Mr. O’Neil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Ionis, Mr. O’Neil was an associate at Cooley LLP.

C. Frank Bennett

Dr. C. Frank Bennett, Ph.D., is Senior Vice President - Antisense Research of Isis Pharmaceuticals, Inc. . From June 1995 to January 2006, Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore.

Richard Geary

Dr. Richard S. Geary , Ph.D. , is Senior Vice President - Development of Ionis Pharmaceuticals Inc. From August 2003 to August 2008, Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.

B. Lynne Parshall

Ms. B. Lynne Parshall, J.D. , is Director and Senior Strategic Advisor of Ionis Pharmaceuticals Inc. Previously she served as our Chief Operating Officer from December 2007 through December 2017 and as our Chief Financial Officer from June 1994 through December 2012. She also served as our Corporate Secretary through 2014, and has served with the Company in various executive roles since November 1991. Prior to joining Ionis, Ms. Parshall practiced law at Cooley LLP, outside counsel to Ionis, where she was a partner from 1986 to 1991. Ms. Parshall is a member of the American and California bar associations. Ms. Parshall serves on the board of directors of Cytokinetcs Inc. and Akcea Therapeutics, Inc., both biopharmaceutical companies. Within the last five years, Ms. Parshall formerly served as a Director of Regulus Therapeutics, Inc.

Damien McDevitt

Dr. Damien McDevitt, Ph.D. is Chief Business Officer of the Company. Dr. McDevitt joins Ionis from ACADIA Pharmaceuticals, where he served as senior vice president, corporate development. Prior to joining ACADIA, Dr. McDevitt was at GSK for more than two decades, where he was instrumental in over 70 global business development transactions involving multiple therapeutic areas, including severe and rare and neuromuscular diseases, among others. He served in various roles with increasing responsibility including vice president, head of business development for R&D Extended Therapy Areas, head of Worldwide Business Development Asia and head of GSK's R&D West Coast Innovation Center. He also worked at GSK Ventures and in anti-infective discovery. Dr. McDevitt is an author of 70 scientific publications and published patents. He attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and undergraduate degree, both in microbiology.

Spencer Berthelsen

Dr. Spencer R. Berthelsen, M.D., is an Independent Director of the Company. Since 1980, he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 400 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He served as Chairman of their Board of Directors from October 2001 through April 2016. He has served as a Clinical Professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005.

Breaux Castleman

Mr. Breaux B. Castleman is Independent Director of Isis Pharmaceuticals, Inc . Since August 2001, Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a healthcare investment company, which sold its operations as a service provider of integrated care management and disease management. Mr. Castleman was a director of USMD Holdings, Inc., a physician-led integrated healthcare system, from September 2009 until October 2016 and was a director of MELA Sciences, Inc., a medical device company, from 2003 until 2011.

Joseph Klein

Mr. Joseph Klein, III, is an Independent Director of Isis Pharmaceuticals Inc. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities.

Joseph Loscalzo

Dr. Joseph Loscalzo, M.D. Ph.D., is an Independent Director of Isis Pharmaceuticals Inc. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Post-training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005. He currently serves on the board of directors of Leap Therapeutics, Inc., a publicly held biopharmaceutical company.

Frederick Muto

Mr. Frederick T. Muto, J.D., is an Independent Director of Isis Pharmaceuticals, Inc. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Ionis, in 1980, became a partner in 1986 and Senior Counsel in 2018. He is a founding partner of Cooley LLP’s San Diego office and was Chair of the firm’s Business Department for a number of years.

Joseph Wender

Mr. Joseph H. Wender is an Independent Director of the Company. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he has been a Senior Consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is co-CEO and minority partner, with his wife, of Colgin Cellars. Since March 2014, Mr. Wender has been a director, and is currently lead director, of Outfront Media, lessors of advertising space on out-of-home advertising structures.

D. Wade Walke

Basic Compensation

Name Fiscal Year Total

Stanley Crooke

7,314,650

Elizabeth Hougen

2,231,780

Brett Monia

2,412,890

Patrick O'Neil

2,177,190

C. Frank Bennett

958,865

Richard Geary

2,311,480

B. Lynne Parshall

5,360,040

Damien McDevitt

--

Spencer Berthelsen

731,941

Breaux Castleman

703,941

Joseph Klein

703,941

Joseph Loscalzo

711,941

Frederick Muto

696,941

Joseph Wender

730,941

D. Wade Walke

--
As Of  31 Dec 2017